Page 186 - HIV/AIDS Guidelines

4. Baciewicz AM, Chrisman CR, Finch CK, et al. Update on rifampin and rifabutin drug interactions. Am J Med Sci.
2008;335(2):126-136.
5. Spradling P, Drociuk D, McLaughlin S, et al. Drug-drug interactions in inmates treated for human immunodeficiency
virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak. Clin Infect Dis.
2002;35(9):1106-1112.
6. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and
Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med.
2003;167(4):603-662.
7. Havlir DV, Gilbert PB, Bennett K, et al. Effects of treatment intensification with hydroxyurea in HIV-infected patients
with virologic suppression. AIDS. 2001;15(11):1379-1388.
8. Zala C, Salomon H, Ochoa C, et al. Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a
regimen of stavudine plus didanosine and nevirapine in primary HIV infection. J Acquir Immune Defic Syndr.
2002;29(4):368-373.

9. Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis. 2004;38(8):e79-
80.

10. Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease
associated with AIDS. An AIDS Clinical Trials Group Study. Ann Intern Med. 1990;113(2):111-117.
11. Hoggard PG, Kewn S, Barry MG, et al. Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in
vitro. Antimicrob Agents Chemother. 1997;41(6):1231-1236.
12. Kearney BP, Sayre JR, Flaherty JF, et al. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate
and didanosine. J Clin Pharmacol. 2005;45(12):1360-1367.
13. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated
human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48(6):2091-2096.
14. Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the
pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2852-2856.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents K-16

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.